306 related articles for article (PubMed ID: 32988402)
1. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.
Shi MJ; Meng XY; Fontugne J; Chen CL; Radvanyi F; Bernard-Pierrot I
Genome Med; 2020 Sep; 12(1):85. PubMed ID: 32988402
[TBL] [Abstract][Full Text] [Related]
2. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
Shi MJ; Meng XY; Lamy P; Banday AR; Yang J; Moreno-Vega A; Chen CL; Dyrskjøt L; Bernard-Pierrot I; Prokunina-Olsson L; Radvanyi F
Eur Urol; 2019 Jul; 76(1):9-13. PubMed ID: 30975452
[TBL] [Abstract][Full Text] [Related]
3. Association of mutation signature effectuating processes with mutation hotspots in driver genes and non-coding regions.
Wong JKL; Aichmüller C; Schulze M; Hlevnjak M; Elgaafary S; Lichter P; Zapatka M
Nat Commun; 2022 Jan; 13(1):178. PubMed ID: 35013316
[TBL] [Abstract][Full Text] [Related]
4. FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
Shi MJ; Fontugne J; Moreno-Vega A; Meng XY; Groeneveld C; Dufour F; Kamoun A; Viborg Lindskrog S; Cabel L; Krucker C; Rapinat A; Dunois-Larde C; Lepage ML; Chapeaublanc E; Levrel O; Dixon V; Lebret T; Almeida A; De Reynies A; Rochel N; Dyrskjøt L; Allory Y; Radvanyi F; Bernard-Pierrot I
Eur Urol; 2023 Jan; 83(1):70-81. PubMed ID: 36273937
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
Nickerson ML; Witte N; Im KM; Turan S; Owens C; Misner K; Tsang SX; Cai Z; Wu S; Dean M; Costello JC; Theodorescu D
Oncogene; 2017 Jan; 36(1):35-46. PubMed ID: 27270441
[TBL] [Abstract][Full Text] [Related]
7. Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma.
Thomsen MB; Nordentoft I; Lamy P; Høyer S; Vang S; Hedegaard J; Borre M; Jensen JB; Ørntoft TF; Dyrskjøt L
Mol Oncol; 2016 Nov; 10(9):1450-1460. PubMed ID: 27582092
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Like-Induced Protein Changes in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Throughout Disease Progression.
Bos MK; Smid M; Sleijfer S; Martens JWM
JCO Precis Oncol; 2022 Jan; 6():e2100190. PubMed ID: 35050709
[TBL] [Abstract][Full Text] [Related]
9. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
10. Passenger Hotspot Mutations in Cancer.
Hess JM; Bernards A; Kim J; Miller M; Taylor-Weiner A; Haradhvala NJ; Lawrence MS; Getz G
Cancer Cell; 2019 Sep; 36(3):288-301.e14. PubMed ID: 31526759
[TBL] [Abstract][Full Text] [Related]
11. Exome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure.
Tokheim C; Bhattacharya R; Niknafs N; Gygax DM; Kim R; Ryan M; Masica DL; Karchin R
Cancer Res; 2016 Jul; 76(13):3719-31. PubMed ID: 27197156
[TBL] [Abstract][Full Text] [Related]
12. Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy.
Heide T; Maurer A; Eipel M; Knoll K; Geelvink M; Veeck J; Knuechel R; van Essen J; Stoehr R; Hartmann A; Altmueller J; Graham TA; Gaisa NT
J Pathol; 2019 Jun; 248(2):230-242. PubMed ID: 30719704
[TBL] [Abstract][Full Text] [Related]
13. Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.
Bányai L; Trexler M; Kerekes K; Csuka O; Patthy L
Elife; 2021 Jan; 10():. PubMed ID: 33427197
[TBL] [Abstract][Full Text] [Related]
14. AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer.
Svoboda M; Meshcheryakova A; Heinze G; Jaritz M; Pils D; Castillo-Tong DC; Hager G; Thalhammer T; Jensen-Jarolim E; Birner P; Braicu I; Sehouli J; Lambrechts S; Vergote I; Mahner S; Zimmermann P; Zeillinger R; Mechtcheriakova D
BMC Genomics; 2016 Aug; 17(1):643. PubMed ID: 27527602
[TBL] [Abstract][Full Text] [Related]
15. Analysis of 7,815 cancer exomes reveals associations between mutational processes and somatic driver mutations.
Poulos RC; Wong YT; Ryan R; Pang H; Wong JWH
PLoS Genet; 2018 Nov; 14(11):e1007779. PubMed ID: 30412573
[TBL] [Abstract][Full Text] [Related]
16. Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features.
Buisson R; Langenbucher A; Bowen D; Kwan EE; Benes CH; Zou L; Lawrence MS
Science; 2019 Jun; 364(6447):. PubMed ID: 31249028
[TBL] [Abstract][Full Text] [Related]
17. Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis.
Petljak M; Alexandrov LB; Brammeld JS; Price S; Wedge DC; Grossmann S; Dawson KJ; Ju YS; Iorio F; Tubio JMC; Koh CC; Georgakopoulos-Soares I; Rodríguez-Martín B; Otlu B; O'Meara S; Butler AP; Menzies A; Bhosle SG; Raine K; Jones DR; Teague JW; Beal K; Latimer C; O'Neill L; Zamora J; Anderson E; Patel N; Maddison M; Ng BL; Graham J; Garnett MJ; McDermott U; Nik-Zainal S; Campbell PJ; Stratton MR
Cell; 2019 Mar; 176(6):1282-1294.e20. PubMed ID: 30849372
[TBL] [Abstract][Full Text] [Related]
18. Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer.
Bellmunt J; Kim J; Reardon B; Perera-Bel J; Orsola A; Rodriguez-Vida A; Wankowicz SA; Bowden M; Barletta JA; Morote J; de Torres I; Juanpere N; Lloreta-Trull J; Hernandez S; Mouw KW; Taplin ME; Cejas P; Long HW; Van Allen EM; Getz G; Kwiatkowski DJ
Cancer Res; 2020 Oct; 80(20):4476-4486. PubMed ID: 32868381
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection.
Rao N; Starrett GJ; Piaskowski ML; Butler KE; Golubeva Y; Yan W; Lawrence SM; Dean M; Garcia-Closas M; Baris D; Johnson A; Schwenn M; Malats N; Real FX; Kogevinas M; Rothman N; Silverman DT; Dyrskjøt L; Buck CB; Koutros S; Prokunina-Olsson L
Cancer Prev Res (Phila); 2023 Oct; 16(10):561-570. PubMed ID: 37477495
[TBL] [Abstract][Full Text] [Related]
20. Identification and analysis of mutational hotspots in oncogenes and tumour suppressors.
Baeissa H; Benstead-Hume G; Richardson CJ; Pearl FMG
Oncotarget; 2017 Mar; 8(13):21290-21304. PubMed ID: 28423505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
